


PHARMACEUTICAL 2020

KEMPHARM INC Rank 263 of 362





PHARMACEUTICAL 2020

KEMPHARM INC Rank 263 of 362

The relative strengths and weaknesses of KEMPHARM INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KEMPHARM INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 490% points. The greatest weakness of KEMPHARM INC is the variable Assets, Current, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is -380%, being 77% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	6,634
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,431
Liabilities, Non-Current	2,069
Other Assets	2,402
Other Compr. Net Income	0
Other Expenses	2,923
Other Liabilities	77,463
Other Net Income	-4,207
Property and Equipment	1,471
Research and Development	19,415
Revenues	12,839
Selling, General and Administrative Expense	10,816

Output Variable	Value in 1000 USD
Assets	10,507
Liabilities	84,963
Expenses	33,154
Stockholders Equity	-74,456
Net Income	-24,522
Comprehensive Net Income	-24,522
Economic Capital Ratio	-380%